115 related articles for article (PubMed ID: 21764590)
21. Saponins derived from the roots of Platycodon grandiflorum inhibit HT-1080 cell invasion and MMPs activities: regulation of NF-kappaB activation via ROS signal pathway.
Lee KJ; Hwang SJ; Choi JH; Jeong HG
Cancer Lett; 2008 Sep; 268(2):233-43. PubMed ID: 18499341
[TBL] [Abstract][Full Text] [Related]
22. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
Nuti E; Orlandini E; Nencetti S; Rossello A; Innocenti A; Scozzafava A; Supuran CT
Bioorg Med Chem; 2007 Mar; 15(6):2298-311. PubMed ID: 17276072
[TBL] [Abstract][Full Text] [Related]
23. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
24. Secretion of gelatinases and activation of gelatinase A (MMP-2) by human rheumatoid synovial fibroblasts.
Smolian H; Aurer A; Sittinger M; Zacher J; Bernimoulin JP; Burmester GR; Kolkenbrock H
Biol Chem; 2001 Oct; 382(10):1491-9. PubMed ID: 11727833
[TBL] [Abstract][Full Text] [Related]
25. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
Kim YM; Jang JW; Lee OH; Yeon J; Choi EY; Kim KW; Lee ST; Kwon YG
Cancer Res; 2000 Oct; 60(19):5410-3. PubMed ID: 11034081
[TBL] [Abstract][Full Text] [Related]
26. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
Shoari A; Rasaee MJ; Kanavi MR; Daraei B
J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
[TBL] [Abstract][Full Text] [Related]
27. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
28. Selective gelatinase inhibitor peptide is effective in targeting tongue carcinoma cell tumors in vivo.
Suojanen J; Vilen ST; Nyberg P; Heikkilä P; Penate-Medina O; Saris PE; Hagström J; Ranta TM; Salo T; Sorsa T; Reunanen J
Anticancer Res; 2011 Nov; 31(11):3659-64. PubMed ID: 22110184
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors.
Gooyit M; Lee M; Hesek D; Boggess B; Oliver AG; Fridman R; Mobashery S; Chang M
Chem Biol Drug Des; 2009 Dec; 74(6):535-46. PubMed ID: 19824893
[TBL] [Abstract][Full Text] [Related]
30. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
[TBL] [Abstract][Full Text] [Related]
31. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
32. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
[TBL] [Abstract][Full Text] [Related]
33. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
[TBL] [Abstract][Full Text] [Related]
34. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
35. 1-furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP.
Park BC; Thapa D; Lee YS; Kwak MK; Lee ES; Choi HG; Yong CS; Kim JA
Eur J Pharmacol; 2007 Jul; 567(3):193-7. PubMed ID: 17507007
[TBL] [Abstract][Full Text] [Related]
36. Low molecular weight inhibitors of matrix metalloproteinases can enhance the expression of matrix metalloproteinase-2 (gelatinase A) without inhibiting its activation.
Kerkvliet EH; Jansen ID; Schoenmaker TA; Docherty AJ; Beertsen W; Everts V
Cancer; 2003 Mar; 97(6):1582-8. PubMed ID: 12627524
[TBL] [Abstract][Full Text] [Related]
37. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
38. A combined molecular modeling study on gelatinases and their potent inhibitors.
Xi L; Du J; Li S; Li J; Liu H; Yao X
J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines.
Gu Y; Lee HM; Golub LM; Sorsa T; Konttinen YT; Simon SR
Ann Med; 2005; 37(6):450-60. PubMed ID: 16203617
[TBL] [Abstract][Full Text] [Related]
40. A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression.
Augé F; Hornebeck W; Laronze JY
Crit Rev Oncol Hematol; 2004 Mar; 49(3):277-82. PubMed ID: 15036267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
